Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation

Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by myeloid dysplasia, peripheral blood cytopenias, and increased risk of progression to acute myeloid leukemia (AML). The standard of care for patients with MDS is hypomethylating age...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Sevilla, Juan Jose, Adema, Vera, Garcia-Manero, Guillermo, Colla, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975331/
https://www.ncbi.nlm.nih.gov/pubmed/36787738
http://dx.doi.org/10.1016/j.xcrm.2023.100940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975331/
https://www.ncbi.nlm.nih.gov/pubmed/36787738
http://dx.doi.org/10.1016/j.xcrm.2023.100940

Ejemplares similares